Sirtex Medical launches state-of-the-art SIROS™ system for advanced SIR-Spheres® resin microspheres delivery

Monday 03 August 2020
WOBURN, Mass. (August 3, 2020) –– Sirtex Medical US Holdings, Inc. (“Sirtex”), a leading manufacturer of targeted liver cancer therapies, announced the launch of SIROS™, an innovative system for the delivery of SIR-Spheres® Y-90 resin microspheres.

SIROS™ provides precise, simple and versatile solution for interventional radiologists to deliver patient-tailored care

SIROS™ offers a visual, intuitive and versatile option for interventional radiologists to deliver SIR-Spheres® to patients with liver cancer. With the system’s visually controlled administration, physicians can determine and adjust the precise quantity and speed of SIR-Spheres® microspheres delivery. Additionally, the system is designed to be simple to use yet versatile enough to allow expanded options for patient-tailored delivery.

SIROS™ intuitive design features a peel-and-place tubing set, a proprietary needleless D-Vial specifically designed to suspend SIR-Spheres® into a vortex that may allow for a more even distribution, and a locking cover to safely secure the microspheres during delivery. A three-step setup further provides quick and simple administration and disposal.

"SIROS™ brings world-class expertise and innovation together to provide interventional radiologists with the support and technology they need to treat patients with liver cancer,” said Kevin R. Smith, Chief Executive Officer of Sirtex. “As established leaders in the industry for more than 20 years, we are pleased to add SIROS™ to our expanding portfolio of technology designed to advance patient care."

About Sirtex
Sirtex is a global healthcare business with offices in the U.S., Australia, Europe and Asia, working to improve outcomes in people with cancer. Sirtex’s current lead product is a targeted radiation therapy for liver cancer called SIR-Spheres® Y-90 resin microspheres. More than 100,000 doses have been supplied to treat patients with liver cancer at more than 1,300 medical centers in over 45 countries. For more information, visit www.sirtex.com. SIR-Spheres® is a registered trademark of Sirtex SIR-Spheres Pty Ltd.


APM-US-063-07-20


###


Now leaving sirtex.com

You are about to leave the Sirtex Web site. This link is provided to you as a service and will take you to a site maintained by a third party who is solely responsible for the content.

Please be aware that Sirtex takes no responsibility for content of these external sites, nor do we endorse, warrant or guarantee the products, services or information described or offered on other internet sites.

Click 'Continue' to proceed to the third-party Web site.

Continue

×

Now leaving sirtex.com

You are about to leave the Sirtex Website. This link is provided to you as a service and will take you to the Sirtex Virtual Booth.

Sirtex is responsible for the content of the Virtual Booth, which is hosted on a website maintained by a third-party. Except for Sirtex’s Virtual Booth experience, please be aware that Sirtex takes no responsibility for the other content of these external sites, nor do we endorse, warrant, or guarantee the products, services or information described or offered on other internet sites.

Continue

×

You are now leaving your current sirtex.com region

The Sirtex site you are linking to is intended only for healthcare practitioners and patients outside your current region. Any products discussed herein may have different approved product labeling; therefore, any information provided may not be appropriate for use in your region.

Click 'Continue' to proceed to the other Sirtex region Web site.

Continue

×

This content is intended for journalists only

By clicking "Yes" you are confirming that you are a journalist. If you are not a journalist, then please click "Go to Homepage" which will direct you to the Sirtex homepage.

Yes Go to Homepage